Several talks expected to focus on the latest treatment updates, as well as some recently published data on COVID-19 symptoms and a commonly-used atopic dermatitis treatment.
Just a quick glimpse at the treatment pipeline shows a lot of promise for dermatologists who are looking for options for their most challenging patients. And a glimpse at the agenda for the upcoming 19th Anniversary Winter Clinical Dermatology in person conference, which begins Friday, January 14, 2022 in Kauai, shows just how much the dermatologists in attendance, and those of you who stay tuned to Dermatology Times® all weekend to read our live coverage from the meeting, will learn about those options.
To kick off the meeting, Dermatology Times® Editorial Board member Mark Lebwohl, MD, will host a challenging cases session on Friday night. Lebwohl told Dermatology Times® he is looking forward to a “jam-packed” meeting.
“Historically, Winter Clinical has been jam-packed with useful information, and this year will be no different,” he said. “Clinical tips that you can use immediately have always been a feature of this meeting.” He said that this is going to be an exciting few upcoming months and years, with “new treatments for rare disorders like generalized pustular psoriasis, pseudoxanthoma elasticum, and blastic plasmacytoid dendritic cell neoplasm” to be discussed.
Other featured sessions from this weekend’s coverage will include a focus on what’s hot in infectious diseases, by Ted Rosen, MD, professor of dermatology at Baylor College of Medicine in Houston, Texas, that will undoubtedly include some thoughts on the recent spike in COVID-19 cases and a talk on some of the latest advancements in treatments for an array of infectious diseases.
A central challenge in dermatology is addressing pediatric patients with skin issues, and Peter A. Lio, MD, who is a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, will tackle this issue in his talk, “what’s hot in pediatric dermatology.” His session will focus on some recently-published data suggesting that a commonly-used atopic dermatitis treatment may attenuate some COVID-19 symptoms. He will also discuss recently published data from phase 3 studies that show efficacy and good tolerance of a drug–device combination containing cantharidin 0.7% (VP-102; Verrica) used to treat molluscum contagiosum.
Throughout the weekend, we’ll also feature coverage of a range of topics from the meeting, including the latest innovations in aesthetic treatments, what’s hot in oncology and biologics, and the latest technological innovations for treating your patients and keeping your office up to date.